Local view for "http://purl.org/linkedpolitics/eu/plenary/2009-11-11-Speech-3-176"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20091111.18.3-176"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Mr President, in the absence of Mr Reul, I will repeat this question that we are putting to the Commission. In accordance with the legal basis of Article 165 of the treaty, the Council Recommendation on measures to combat neurodegenerative diseases calls for Parliament to be consulted.
We want to know whether the Council can confirm its intention to adopt conclusions on this issue during the Competitiveness Council of 3 December 2009. Moreover, since Parliament was consulted on the Commission’s proposal, is the Council prepared to take Parliament’s views into account when drafting its conclusions?
Next, regarding possible future joint programming of research activities, can the Council confirm its opinion that these initiatives should, in principle, be adopted using the same legal basis?
I should like to point out that we have drafted a resolution. This resolution has the support of all the political groups and it is important because, quite simply, it highlights the challenges of an ageing population – these challenges that mean that, today, in Europe, we have more than seven million people suffering from Alzheimer’s disease, a figure that it is estimated will double over the next 20 years.
It is therefore crucial to plan, invest and cooperate in this area in order to control the social costs of these diseases, and to offer hope, dignity and a healthier life to the millions of sufferers and their families. These health and social problems, which affect the whole of Europe, require coordinated measures designed to ensure the effectiveness of the prevention, diagnoses, treatment and care provided to the people concerned.
Special attention must be paid to support for the research and innovation work carried out by public and private operators in an effort to find new cures and to prevent the development of these diseases. Health research is even more fragmented at European level, and the number of public-private partnerships must be increased. The example of the Innovative Medicines initiative, launched in February 2008, must not remain a one-off experiment.
I shall conclude by saying that this really is a race against the clock, for we must forestall these diseases as much as possible. Research today shows that there are already initiatives aimed at pre-diagnosis. It is on these concrete issues that our fellow citizens are expecting signals from the Europe for health, which must give guarantees and anticipate the development of age-related diseases."@en1
|
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples